FBXL12

FBXL12 is the substrate-recognition subunit of SCF(FBXL12) E3 ubiquitin ligase complexes that target diverse substrates for proteasomal degradation, thereby governing DNA repair pathway choice, replication fork integrity, cell cycle progression, and stem cell differentiation. At DNA double-strand breaks, SCF(FBXL12) polyubiquitinates Ku80 to limit Ku accumulation on DNA ends, restricting end resection in quiescent cells and preserving transcription near breaks (PMID:23324393, PMID:35575473, PMID:39058590). SCF(FBXL12) also degrades FANCD2 at stalled replication forks via a CHK1-generated phosphodegron, preventing FANCD2 trapping on chromatin and replication stress (PMID:37591242), and targets ALDH3 family members to drive trophoblast stem cell differentiation in placenta and DP-to-SP thymocyte maturation in thymus (PMID:26124079, PMID:26999371). Additional substrates include p57(KIP2) in osteoblasts (PMID:18660753), p27/Cdkn1b downstream of pre-TCR signaling during β-selection (PMID:31451788), CaMKI in lung epithelial G1 arrest (PMID:23707388), and ALDH1A1 in pancreatic cancer cells (PMID:40055736).

1. 2008 High

   Identification of the first SCF(FBXL12) substrate established FBXL12 as a functional E3 ligase subunit that targets the CDK inhibitor p57(KIP2) for phosphorylation-dependent ubiquitylation and degradation during osteoblast differentiation.

   Evidence Co-IP, in vitro ubiquitylation, RNAi, and dominant-negative approaches in osteoblast cultures

   PMID:18660753

   Open questions at the time

   • Phosphorylation site on p57 required for FBXL12 recognition not mapped
   • In vivo relevance in skeletal development not tested
2. 2013 High

   Discovery that FBXL12 ubiquitylates Ku80 at DNA double-strand breaks—using an unusual F-box domain for both Skp1 and substrate binding—revealed a direct role in DNA repair pathway choice by removing the NHEJ factor Ku from break sites.

   Evidence Xenopus egg extract immunodepletion, DSB-binding screen, in vitro ubiquitylation reconstitution

   PMID:23324393

   Open questions at the time

   • Structural basis for dual F-box domain interactions unresolved
   • Mammalian in vivo validation not performed
3. 2013 Medium

   Identification of CaMKI as an FBXL12 substrate linked FBXL12 to cell cycle control in lung epithelium, showing that CaMKI degradation disrupts cyclin D1/cdk4 assembly and blocks G1 progression through impaired p27 phosphorylation.

   Evidence Overexpression and RNAi in lung epithelial cells with proteasome inhibition and phosphosite mutagenesis

   PMID:23707388

   Open questions at the time

   • Direct FBXL12–CaMKI binding not demonstrated by in vitro reconstitution
   • In vivo lung phenotype not examined
4. 2015 High

   Knockout mouse studies revealed that FBXL12-mediated ALDH3 degradation is essential for trophoblast stem cell differentiation during placental development, expanding the substrate repertoire to metabolic enzymes controlling stemness.

   Evidence FBXL12 KO mouse, in vitro ubiquitylation, forced ALDH3 expression and inhibitor rescue

   PMID:26124079

   Open questions at the time

   • ALDH3 degron motif uncharacterized
   • Whether FBXL12 requires ALDH3 post-translational modification for recognition unknown
5. 2016 High

   Extension of the ALDH3-degradation axis to the thymus showed that FBXL12 is required cell-autonomously for the DP-to-SP thymocyte transition, demonstrating tissue-specific deployment of the same substrate-targeting mechanism.

   Evidence FBXL12 KO mouse with bone marrow transplantation and fetal thymic organ culture

   PMID:26999371

   Open questions at the time

   • Precise ALDH3-dependent metabolic pathway disrupting thymocyte maturation not identified
   • Redundancy with other F-box proteins in thymus not tested
6. 2019 High

   Genetic epistasis in mouse thymocytes showed that FBXL12 and FBXL1 are transcriptionally induced by pre-TCR and Notch signals, respectively, to cooperatively degrade p27/Cdkn1b and drive proliferative expansion during β-selection.

   Evidence Genetic mouse models with flow cytometry, proliferation assays, and epistasis analysis

   PMID:31451788

   Open questions at the time

   • Whether FBXL12 and FBXL1 target distinct p27 phosphoforms not determined
   • Direct biochemical reconstitution of cooperative degradation not shown
7. 2022 Medium

   A genome-wide CRISPR screen in quiescent cells demonstrated that FBXL12-mediated Ku removal limits MRE11/CtIP-dependent DNA end resection in G0, establishing FBXL12 as a regulator of resection in non-cycling cells.

   Evidence CRISPR screen with FBXL12 depletion and resection assays in G0-synchronized cells

   PMID:35575473

   Open questions at the time

   • Whether Ku80 ubiquitylation is the sole mechanism limiting resection in G0 not confirmed
   • Contribution in primary quiescent tissues not tested
8. 2023 High

   Discovery of the CHK1-phosphorylated phosphodegron on FANCD2 as the FBXL12 recognition signal at stalled forks provided the first fully resolved degron mechanism for SCF(FBXL12) and linked it to replication stress tolerance and the Fanconi anemia pathway.

   Evidence In vitro ubiquitylation, phosphodegron mutagenesis, DNA fiber assays, reconstitution in FANCD2-deficient fibroblasts

   PMID:37591242

   Open questions at the time

   • Crystal structure of FBXL12–phosphodegron complex unavailable
   • Whether FBXL12 also targets monoubiquitinated FANCD2 not addressed
9. 2024 Medium

   Live-cell imaging and neddylation inhibition studies showed that FBXL12-dependent removal of Ku operates throughout the cell cycle to limit Ku to 1–2 molecules per DNA end, preventing excessive chromatin invasion and transcriptional impairment near breaks.

   Evidence Live-cell imaging, neddylation inhibition, FBXL12 depletion, transcription assays near DSBs

   PMID:39058590

   Open questions at the time

   • Whether additional E3 ligases cooperate with FBXL12 for Ku removal not resolved
   • Quantitative kinetics of Ku turnover at single breaks not fully modeled
10. 2025 Medium

    Identification of K63-linked ubiquitylation of MYH14 in microglia extended FBXL12 function beyond proteasomal degradation to non-degradative signaling, linking it to cytoskeletal reorganization and scar-less healing after spinal cord injury.

    Evidence Multiomics, K63-linkage-specific ubiquitylation assay, microglial migration assays, spinal cord injury mouse model

    PMID:40830106

    Open questions at the time

    • Whether K63-linked ubiquitylation is directly catalyzed by SCF(FBXL12) or requires an accessory E2 not established
    • Generalizability of non-degradative FBXL12 activity to other contexts unknown
11. 2025 Medium

    The PAX5–FBXL12–ALDH1A1 axis in pancreatic cancer revealed transcriptional regulation of FBXL12 as a control layer, with sorcin sequestering PAX5 to suppress FBXL12 expression and protect ALDH1A1 from ubiquitylation.

    Evidence ChIP, luciferase reporter, Co-IP, siRNA, ubiquitylation assays in pancreatic cancer cells

    PMID:40055736

    Open questions at the time

    • Direct FBXL12–ALDH1A1 degron characterization lacking
    • Whether PAX5-dependent FBXL12 regulation operates outside pancreatic cancer unknown

• No structural model of FBXL12 bound to any substrate or degron exists, and the basis for its unusually broad substrate repertoire—spanning Ku80, FANCD2, p57, p27, CaMKI, ALDH3, ALDH1A1, and MYH14—remains mechanistically unexplained.
• No crystal or cryo-EM structure of FBXL12 or any FBXL12–substrate complex
• Whether leucine-rich repeats confer distinct degron-binding modes for different substrates unknown
• Relative contribution of FBXL12 versus other F-box proteins at shared substrates (e.g., p27) not quantified in vivo